Key facts
- It has raised $73.9M; the latest was Later Stage VC ($48.7M) in Sep 2024.
- Notable investors include Innosuisse, Monte Carlo Capital, Wellington Partners, Panakes Partners, Korys Investments — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for CorFlow
- ·The full record, as it builds
Funding rounds
No funding rounds for CorFlow are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CorFlow
Developer of a diagnostic and therapeutic medical device designed to improve the quality of human life with a relentless pursuit to solve unmet medical needs. The company's controlled flow infusion system measures the degree of microvascular obstruction using a proprietary and dynamic microvascular resistance concept and compares these peri-procedural dMVR values to post-procedure contrast-enhanced magnetic resonance imaging, enabling interventional cardiologists to diagnose and treat microvascular obstruction in severe heart attack patients.
- Sector
- Healthcare
- HQ
- Baar, Switzerland
- Founded
- 2016
- Employees
- 25
- Website
- corflow.com/
- Ownership
- Privately Held (backing)
CorFlow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CorFlow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CorFlow in its N-PORT filings yet. We sweep new filings monthly.